Oncotelic Therapeutics Inc. has unveiled preclinical data demonstrating that its Deciparticle nanomedicine platform can transform hydrophobic drugs into uniform, intravenous-ready nanoparticles, with its Sapu003 formulation of Everolimus showing a 67-fold reduction in gastrointestinal drug accumulation compared to oral dosing. This advancement represents a significant step toward safer and more effective cancer treatments by potentially minimizing toxic side effects associated with current oral administration methods.
The company presented this data at the 2025 San Antonio Breast Cancer Symposium, highlighting how the platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into nanoparticles small enough for effective intravenous use. According to the presentation available at https://ibn.fm/LxQ7N, the technology shows high compatibility across therapeutic categories, with all five main macrolide mTOR inhibitors forming stable, monodisperse particles suitable for clinical development.
This development matters because gastrointestinal toxicity represents a major limitation in cancer treatment, often forcing dose reductions or treatment discontinuations that compromise patient outcomes. By dramatically reducing drug accumulation in the gastrointestinal tract while maintaining therapeutic efficacy through intravenous delivery, Oncotelic's platform could enable higher, more consistent dosing with fewer side effects. For patients undergoing treatment with drugs like Everolimus (marketed as Afinitor), this could mean better tolerance of therapy and improved quality of life during treatment.
The implications extend beyond individual patient care to the broader oncology and immunology fields. The platform's modular, cGMP-ready engineering allows for rapid development of multiple drug formulations, potentially accelerating the pipeline of new treatments. As Oncotelic expands its immunology and oncology pipeline based on this nanotechnology, the approach could transform how hydrophobic drugs—which constitute a significant portion of cancer therapeutics—are delivered and tolerated by patients.
For the pharmaceutical industry, this represents a shift toward next-generation drug delivery systems that address fundamental limitations of existing formulations. The ability to reliably package water-resistant drugs into intravenous nanoparticles opens new possibilities for drug development and reformulation, potentially extending the therapeutic window of existing medications and enabling new combination therapies. As nanomedicine continues to evolve, platforms like Deciparticle demonstrate how targeted delivery systems can improve both safety profiles and clinical outcomes in challenging therapeutic areas.
